PubRank

Martin F Bachmann

Author PubWeight™ 128.68‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 mTOR regulates memory CD8 T-cell differentiation. Nature 2009 10.07
2 Interleukin-1 is responsible for acute lung immunopathology but increases survival of respiratory influenza virus infection. J Virol 2005 3.14
3 Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008 2.97
4 Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 2008 2.77
5 Regulation of homeostatic chemokine expression and cell trafficking during immune responses. Science 2007 2.67
6 Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 2004 2.59
7 Complement component C3 promotes T-cell priming and lung migration to control acute influenza virus infection. Nat Med 2002 2.54
8 The human membrane cofactor CD46 is a receptor for species B adenovirus serotype 3. J Virol 2004 2.11
9 A vaccine against nicotine for smoking cessation: a randomized controlled trial. PLoS One 2008 2.07
10 TLR9 signaling in B cells determines class switch recombination to IgG2a. J Immunol 2007 1.95
11 The coming of age of virus-like particle vaccines. Biol Chem 2008 1.85
12 Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur J Immunol 2006 1.84
13 A therapeutic vaccine for nicotine dependence: preclinical efficacy, and Phase I safety and immunogenicity. Eur J Immunol 2005 1.84
14 Neutralization of IL-17 by active vaccination inhibits IL-23-dependent autoimmune myocarditis. Eur J Immunol 2006 1.75
15 Nonmethylated CG motifs packaged into virus-like particles induce protective cytotoxic T cell responses in the absence of systemic side effects. J Immunol 2004 1.74
16 Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 2011 1.70
17 A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J Hypertens 2007 1.68
18 CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cells. Immunity 2005 1.63
19 Cutting edge: identification of E-cadherin as a ligand for the murine killer cell lectin-like receptor G1. J Immunol 2006 1.59
20 VSIG4, a B7 family-related protein, is a negative regulator of T cell activation. J Clin Invest 2006 1.51
21 A molecular assembly system that renders antigens of choice highly repetitive for induction of protective B cell responses. Vaccine 2002 1.48
22 Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol 2002 1.39
23 Nrf2 is essential for cholesterol crystal-induced inflammasome activation and exacerbation of atherosclerosis. Eur J Immunol 2011 1.37
24 Averting inflammation by targeting the cytokine environment. Nat Rev Drug Discov 2010 1.36
25 Constitutive crosspresentation of tissue antigens by dendritic cells controls CD8+ T cell tolerance in vivo. Immunity 2008 1.34
26 Inflammasome activation and IL-1β target IL-1α for secretion as opposed to surface expression. Proc Natl Acad Sci U S A 2011 1.33
27 Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol 2010 1.32
28 Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. Eur J Immunol 2008 1.30
29 Role of Toll-like receptors in costimulating cytotoxic T cell responses. Eur J Immunol 2003 1.26
30 Innate signals compensate for the absence of PKC-{theta} during in vivo CD8(+) T cell effector and memory responses. Proc Natl Acad Sci U S A 2005 1.21
31 Isolation of human monoclonal antibodies by mammalian cell display. Proc Natl Acad Sci U S A 2008 1.14
32 A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J Immunol 2007 1.13
33 Rapid response of marginal zone B cells to viral particles. J Immunol 2004 1.13
34 Regulation of memory antibody levels: the role of persisting antigen versus plasma cell life span. J Immunol 2007 1.12
35 Versatile virus-like particle carrier for epitope based vaccines. PLoS One 2010 1.12
36 Mechanisms of allergen-specific desensitization. J Allergy Clin Immunol 2010 1.11
37 Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol 2006 1.11
38 Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin Investig Drugs 2007 1.11
39 Critical role for activation of antigen-presenting cells in priming of cytotoxic T cell responses after vaccination with virus-like particles. J Immunol 2002 1.10
40 Innate immunity together with duration of antigen persistence regulate effector T cell induction. J Immunol 2003 1.09
41 Innate immunity mediates follicular transport of particulate but not soluble protein antigen. J Immunol 2012 1.09
42 Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection. Eur J Immunol 2012 1.09
43 Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur J Immunol 2008 1.07
44 Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol 2002 1.07
45 Potent T cell agonism mediated by a very rapid TCR/pMHC interaction. Eur J Immunol 2007 1.06
46 Immunodrugs: therapeutic VLP-based vaccines for chronic diseases. Annu Rev Pharmacol Toxicol 2009 1.05
47 Blocking IL-1α but not IL-1β increases susceptibility to chronic Mycobacterium tuberculosis infection in mice. Vaccine 2010 1.05
48 Memory and effector CD8 T-cell responses after nanoparticle vaccination of melanoma patients. J Immunother 2010 1.04
49 Complement receptors regulate differentiation of bone marrow plasma cell precursors expressing transcription factors Blimp-1 and XBP-1. J Exp Med 2005 1.04
50 The second-generation active Aβ immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci 2011 1.03
51 Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr Mol Med 2007 1.03
52 A VLP-based vaccine targeting domain III of the West Nile virus E protein protects from lethal infection in mice. Virol J 2010 1.03
53 Vaccination against GIP for the treatment of obesity. PLoS One 2008 1.01
54 Th cells act via two synergistic pathways to promote antiviral CD8+ T cell responses. J Immunol 2010 1.01
55 Virus-like particles as carriers for T-cell epitopes: limited inhibition of T-cell priming by carrier-specific antibodies. J Virol 2005 1.01
56 Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients. Eur J Immunol 2012 1.01
57 Role of IgM antibodies versus B cells in influenza virus-specific immunity. Eur J Immunol 2002 1.00
58 Exploiting viral properties for the rational design of modern vaccines. Expert Rev Vaccines 2008 0.99
59 Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J Immunol 2009 0.98
60 Osteopontin is not required for the development of Th1 responses and viral immunity. J Immunol 2005 0.96
61 Carrier induced epitopic suppression of antibody responses induced by virus-like particles is a dynamic phenomenon caused by carrier-specific antibodies. Vaccine 2010 0.94
62 Innate signaling regulates cross-priming at the level of DC licensing and not antigen presentation. Eur J Immunol 2010 0.94
63 Efficient homologous prime-boost strategies for T cell vaccination based on virus-like particles. Eur J Immunol 2005 0.94
64 Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 2009 0.94
65 Secretory phospholipase A2-IID is an effector molecule of CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A 2009 0.93
66 Loading of MHC class I and II presentation pathways by exogenous antigens: a quantitative in vivo comparison. J Immunol 2004 0.92
67 Kinetic and mechanistic requirements for helping CD8 T cells. J Immunol 2008 0.91
68 Potent inhibition of angiogenesis by D,L-peptides derived from vascular endothelial growth factor receptor 2. Thromb Haemost 2003 0.91
69 Protection against osteoporosis by active immunization with TRANCE/RANKL displayed on virus-like particles. J Immunol 2005 0.90
70 Prophylactic and therapeutic activity of fully human monoclonal antibodies directed against influenza A M2 protein. Virol J 2009 0.90
71 Cutting edge: limited specialization of dendritic cell subsets for MHC class II-associated presentation of viral particles. J Immunol 2009 0.90
72 Immunization strategies for Clostridium difficile infections. Expert Rev Vaccines 2012 0.88
73 Virus-induced humoral immunity: on how B cell responses are initiated. Curr Opin Virol 2013 0.88
74 CD36 is differentially expressed on B cell subsets during development and in responses to antigen. J Immunol 2008 0.87
75 The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma. J Allergy Clin Immunol 2013 0.86
76 IL-21 induces death of marginal zone B cells during chronic inflammation. Blood 2010 0.86
77 Virus-like particles as a modular system for novel vaccines. Intervirology 2002 0.85
78 Enhanced apoptotic activity of a structurally optimized form of galectin-1. Mol Immunol 2004 0.85
79 Virus-like particles induce robust human T-helper cell responses. Eur J Immunol 2011 0.85
80 Vaccines against non-communicable diseases. Curr Opin Immunol 2010 0.84
81 Bacterially produced recombinant influenza vaccines based on virus-like particles. PLoS One 2013 0.83
82 Different binding modes of free and carrier-protein-coupled nicotine in a human monoclonal antibody. J Mol Biol 2011 0.81
83 Follicular and marginal zone B cells fail to cross-present MHC class I-restricted epitopes derived from viral particles. J Immunol 2009 0.81
84 Immunization against angiotensins for the treatment of hypertension. Clin Immunol 2009 0.81
85 Low-affinity B cells transport viral particles from the lung to the spleen to initiate antibody responses. Proc Natl Acad Sci U S A 2012 0.81
86 CpG oligodeoxynucleotides block human immunodeficiency virus type 1 replication in human lymphoid tissue infected ex vivo. J Virol 2004 0.80
87 A VLP-based vaccine against interleukin-1α protects mice from atherosclerosis. Eur J Immunol 2013 0.80
88 Dissection of seroreactivity against the tryptophan-rich motif of the feline immunodeficiency virus transmembrane glycoprotein. Virology 2004 0.80
89 Therapeutic vaccines for nicotine dependence. Curr Opin Mol Ther 2006 0.79
90 Heterogeneous antibody repertoire of marginal zone B cells specific for virus-like particles. Microbes Infect 2007 0.79
91 T cell-dependent and -independent IgA responses: role of TLR signalling. Immunol Invest 2010 0.79
92 Immunodrugs: breaking B- but not T-cell tolerance with therapeutic anticytokine vaccines. Immunotherapy 2010 0.79
93 A virus-like particle-based anti-nerve growth factor vaccine reduces inflammatory hyperalgesia: potential long-term therapy for chronic pain. J Immunol 2010 0.78
94 A second vaccine revolution for the new epidemics of the 21st century. Drug Discov Today 2006 0.78
95 Identification of Ly-6K as a novel marker for mouse plasma cells. Mol Immunol 2008 0.77
96 Limited in vivo reactivity of polyclonal effector cytotoxic T cells towards altered peptide ligands. Microbes Infect 2005 0.77
97 Immunotherapy of type-1 allergies with virus-like particles and CpG-motifs. Expert Rev Clin Immunol 2014 0.76
98 Enhanced neutralizing antibody titers and Th1 polarization from a novel Escherichia coli derived pandemic influenza vaccine. PLoS One 2013 0.76
99 Therapeutic vaccination to block receptor-ligand interactions. Expert Opin Biol Ther 2003 0.76
100 Function of marginal zone B cells in antiviral B-cell responses. Crit Rev Immunol 2005 0.76
101 Reply to 'Blood pressure vaccine shot down by safety concerns'. Nat Med 2006 0.75
102 Allergen-specific immunotherapy: regulatory T cells or allergen-specific IgG? Hum Vaccin 2010 0.75
103 Targeting osteoporosis and rheumatoid arthritis by active vaccination against RANKL. Adv Exp Med Biol 2007 0.75
104 Hybrid Sindbis/Epstein-Barr virus episomal expression vector for inducible production of proteins. Biotechniques 2005 0.75
105 Rapid functional cloning of cell adhesion molecules. Biotechniques 2004 0.75
106 On the role of APC-activation for in vitro versus in vivo T cell priming. Cell Immunol 2003 0.75
107 Immunotherapies: cause for measured optimism. Drug Discov Today 2002 0.75
108 Combined vaccination against IL-5 and eotaxin blocks eosinophilia in mice. Vaccine 2010 0.75
109 The True Story and Advantages of RNA Phage Capsids as Nanotools. Intervirology 2016 0.75
110 Protective effect of a germline, IL-17-neutralizing antibody in murine models of autoimmune inflammatory disease. Eur J Immunol 2015 0.75